Adverse Effects on cognition and Efficacy of Brief Pulse and Ultra Brief Pulse-width electroconvulsive therapy in Patients of Schizophrenia

Not Applicable

• Conditions: Health Condition 1: F20- Schizophrenia

• Registration Number: CTRI/2021/07/034763
• Lead Sponsor: Central Institute Of Psychiatry Kanke Ranchi

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: ot Yet Recruiting
• Sex: Not specified
• Target Recruitment: 0

Inclusion Criteria

1. Diagnosis of Schizophrenia using Diagnostic Criteria for Research (DCR) of International

Classification of Disease-10th edition (ICD-10, World Health Organization,1992)

2. Age between 18- 60 years of either sex

3. Calgary Depression Scale for Schizophrenia (CDSS) score less than 7

4. Patients meeting any of the indications of ECT in Schizophrenia (Treatment Guidelines of

Indian Psychiatry Society-2017):

• Affective Symptoms

• Need for rapid control of symptoms

• Presence of suicidal behaviour putting patientâ??s life at risk

• Presence of severe agitation or violence putting otherâ??s life at risk

• Refusal to eat, putting patientâ??s life at risk

• History of good response in the past

• Patient not responding to adequate trial of an antipsychotic medication

• Augmentation of partial response to antipsychotic medication

• Clozapine resistant schizophrenia

• Not able to tolerate antipsychotic medications

5. Patients giving written informed consent for ECT and the study

Exclusion Criteria

1. Co-morbid neurological or other psychiatric disorder (current or in past).

2. Patient with co morbid substance dependence or abuse in last 6 months, except nicotine

and caffeine.

3. Subjects who have received ECT in past 6 months.

4. Baseline score of less than 24 on Mini Mental Status Examination (MMSE

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Primary outcome of the study is to study the cognitive side effect of ultrabrief pulse and brief pulse <br/ ><br>ECT as measured by Montreal Cognitive Assessment (MoCATimepoint: after 1-2days of first and eighth session of ECT.

Secondary Outcome Measures

Name	Time	Method
Secondary outcomes are the clinical <br/ ><br>improvement in patients with schizophrenia as recorded on The Positive and Negative Syndrome <br/ ><br>Scale for Schizophrenia (PANSS) and overall severity score on Clinical Global Impression-Severity <br/ ><br>Index (CGI-SI) and changes in Neuron- specific enolase <br/ ><br>level as measured by ELISATimepoint: after 1-2days of first and eighth session of ECT.